Here are seven notes:
1. In 2015, the market reached $55.63 billion.
2. The global orthopedic biomaterials market is expected grow at a compound annual growth rate of 18.6 percent to 2022.
3. The growing demand for treatment involving biomaterial implants and stem cell therapy will spur the market’s growth.
4. Strict regulatory laws, poor reimbursements and post-implantation issues will pose as obstacles to the market’s growth.
5. The metallic segment will dominate the market, and the polymer biomaterials segment will be the fastest-growing segment.
6. North America is anticipated to dominate the global market because of more plastic surgeries and cancer cases.
7. BASF SE, Invibio, Carpenter Technology, Covalon Technologies, Zimmer Biomet, Cam Orthopedic Biomaterials, Exactech and Aesculap are some of the key market players.
More articles on devices:
Anika Therapeutics’ total revenue up 44% to $22.3M — 5 things to know
Zimmer Biomet, NuVasive, Wenzel Spine & more: 21 key notes
Stryker to launch Tritanium Posterior Lumbar Cage: 4 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
